Biblio

Author Title [ Type

] Year

Filters: Author is Gill, Harinder [Clear All Filters]

Journal Article

Li VWK, Yim R, Lee P, Chin L, Au L, Leung GMK, Sim J, Lie AKW, Tse E, Kwong Y-L, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reaction. Ann Hematol. 2023.

Rienhoff HYoung, Gill H. Bomedemstat as an investigative treatment for myeloproliferative neoplasms. Expert Opin Investig Drugs. 2023.

Gill H, Leung AYH, Chan C-C, Lau JSM, Chan C, Yip S-F, Liu H, Kho B, Mak V, Lee HKK, et al. Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis. Hematology. 2015.

Gill H, Yim R, Pang HH, Lee P, S Y Chan T, Hwang Y-Y, Leung GMK, Ip H-W, Y Y Leung R, Yip S-F, et al. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation. Cancer Med. 2020.

Gill H, Leung GMK, Ooi MGM, Z Y Teo W, Wong C-L, Choi CWon, Wong G-C, Lao Z, Rojnuckarin P, Castillo MRosario Ir, et al. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group. Clin Exp Med. 2023.

Gill H, Leung AYH, Kwong Y-L. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy. Int J Mol Sci. 2016;17(4).